John Fahey, Ph.D. There is excitement on the frontiers of cardiovascular research with the recent announcement by Merck that they have a drug in development which raised HDL-cholesterol in study participants by 138% from 41 mg/dL to 101 mg/dL in a clinical trial. The drug is Anacetrapib. The...

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]